Moderna COVID-19 Vaccine Active Against Emerging Variants – MPR
In vitro neutralization studies of sera from individuals vaccinated with Moderna’s COVID-19 vaccine showed that vaccination produced neutralizing titers against key emerging variants.
In vitro neutralization studies of sera from individuals vaccinated with Moderna’s COVID-19 vaccine showed that vaccination produced neutralizing titers against key emerging variants.
The approval was based on data from the phase 3 VISIBLE 2 trial.
The shortage is expected to continue at least through the second quarter of 2024.
SuVax is a subunit protein vaccine of recombinantly expressed Sudan ebolavirus glycoprotein.
A record high of 323 different meds were in short supply during the first quarter of 2024,
The double-blind, phase 3 study included 2 groups of patients, those who were not on positive airway pressure therapy and those who were.
All of the affected individuals were females who received the injections in non-health care settings by untrained individuals who purchased the product from unlicensed sources.
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway.
The Repatha Pushtronix System will be discontinued as of June 30, 2024.
The kit includes a lesion swab, collection tube, and a return package to an authorized laboratory for analysis.
The table below is a review of notable updates that occurred in March 2024 for investigational products in development.